Sintilimab treatment for chronic active Epstein-Barr virus infection and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children.
Ruyue ChenQiang LinYun ZhuYunyan ShenQinying XuHanyun TangNingxun CuiLu JiangXiaomei DaiWeiqing ChenXiao-Zhong LiPublished in: Orphanet journal of rare diseases (2023)
Our data supported the efficacy of PD-1 targeted therapy in certain patients with CAEBV and EBV-HLH, and suggested that sintilimab could provide a cure for these diseases, without HSCT. More prospective studies and longer follow-up are needed to confirm these conclusions.